Turn Therapeutics highlighted GX-03, a topical, non-systemic immunomodulator targeting IL-36 and downstream cytokines, with initial focus on moderate-to-severe atopic dermatitis.
Phase 2 randomized trial in atopic dermatitis remains in progress; topline results are expected in Q4 2026.
Stage 1 completed in June 2026 with 50 patients; Stage 2 targets about 120-135 patients in an adaptive, vehicle-controlled design.
Interim subgroup showed Week 4 vIGA-AD success of 61.5% for GX-03 versus 8.3% for vehicle; p=0.01.
Pipeline milestones include a Type B FDA meeting in Q4 2026; Phase 3 initiation targeted for mid-2027.
TTRX•
